Terminology Verification and Hallucination Prevention in Regulated Life Sciences Translations
In pharmaceutical and medical device localization, even a single misrendered dosage unit or omitted contraindication carries severe patient-safety risk. Multi-layered deterministic QA combined with dual-linguist ISO 17100 review remains mandatory.
Why Probabilistic Models Alone Cannot Guarantee Patient Safety
Neural translation models and Large Language Models operate by predicting probable token sequences. While this probabilistic nature produces fluent sentences, it also introduces a non-zero risk of silent numerical transposition (e.g., `15 mg` vs. `50 mg`), unit conversion errors (`mmol/L` vs. `mg/dL`), or the dropping of negative prefixes (*non-absorbable*, *contraindicated in*). In regulated life sciences documentation—such as SmPCs, Package Leaflets, IFUs, and clinical trial protocols—probabilistic fluency is never a substitute for deterministic verification.
Deterministic Regex/Tag QA + Independent Medical Revision
Best-practice medical localization workflows enforce a strict three-tier safety architecture: first, locked translation memories and EMA MedDRA/EDQM termbases constrain initial drafting; second, deterministic programmatic QA checks verify 100% numeric, dosage-unit, XML-tag, and non-breaking space parity; third, an independent second medical linguist performs full bilingual revision in accordance with ISO 17100:2015.
Executive Takeaways for Global Enterprises
- Key Insight: Probabilistic neural models require deterministic programmatic QA to verify numbers, dosages, and negative prefixes.
- Key Insight: MedDRA and EDQM standard terms must be locked in the project termbase across all EEA languages.
- Key Insight: Independent bilingual revision by a qualified medical specialist under ISO 17100 ensures patient safety.
Benötigen Sie zertifizierte mehrsprachige Übersetzungen, beglaubigte Fachübersetzungen oder ISO-konforme Lokalisierung für Ihre internationalen Projekte? Fordern Sie ein kostenloses individuelles Angebot von Alphatrad an und erhalten Sie innerhalb von 24 Stunden eine detaillierte Rückmeldung.
Editorial & Copyright Attribution Note: This industry analysis has been independently synthesized and adapted by Alphatrad’s editorial team based on verified regulatory documentation and industry research originally published by European Medicines Agency (EMA) & ISO 17100 Quality Guidelines. For the original publication and primary documentation, please consult:
Source: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/product-information-requirements
Hinterlassen Sie einen Kommentar
Wollen Sie an der Diskussion teilnehmen?Wir freuen uns über ihren Beitrag!